{
    "id": 20457,
    "fullName": "ETV1 rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ETV1 rearrange indicates an unspecified rearrangement of the ETV1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 2115,
        "geneSymbol": "ETV1",
        "terms": [
            "ETV1",
            "ER81"
        ]
    },
    "variant": "rearrange",
    "createDate": "03/29/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20805,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the presence of ETV1 rearrangement was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 20932,
                "profileName": "ETV1 rearrange"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5475,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YK-4-279 inhibited invasion and motility of a prostate cancer cell line with an ETV1 rearrangement in culture (PMID: 21559405).",
            "molecularProfile": {
                "id": 20932,
                "profileName": "ETV1 rearrange"
            },
            "therapy": {
                "id": 3419,
                "therapyName": "YK-4-279",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4357,
                    "pubMedId": 21559405,
                    "title": "YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21559405"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20932,
            "profileName": "ETV1 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}